Viral Arthritis Vaccine Market Report 2026

The viral arthritis vaccine market size has grown rapidly in recent years. It will grow from $6.66 billion in 2025 to $7.36 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to chikungunya outbreak history, vaccine platform advances, global immunization programs, zoonotic virus research, public health preparedness efforts.

The viral arthritis vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to next generation vaccine platforms, emerging arbovirus threats, accelerated clinical trials, global travel related exposure, preventive immunization expansion. Major trends in the forecast period include mrna based viral arthritis vaccines, recombinant vector vaccine platforms, multivalent arthritogenic virus vaccines, rapid response vaccine design, adjuvanted immunogenic formulations.

A growing incidence of mosquito-borne viral infections is expected to propel the expansion of the viral arthritis vaccine market in the coming years. Mosquito-borne viral infections are diseases transmitted to humans via infected mosquito bites, including chikungunya, Zika, and dengue viruses, which can cause fever, joint pain, rashes, and, in some cases, long-term complications like viral arthritis. Their prevalence is increasing due to climate change, which creates warmer temperatures and altered rainfall patterns, expanding mosquito habitats and breeding seasons. Viral arthritis vaccines help mitigate mosquito-borne infections by preventing virus-related infection and disease progression, thereby reducing transmission risks and disease burden among populations. For instance, in 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, more than 7.6 million cases were reported globally by April, tripling the number recorded during the same period in 2023, with transmission continuing across over 90 countries. Therefore, the rising incidence of mosquito-borne viral infections is driving the viral arthritis vaccine market.

Leading companies operating in the viral arthritis vaccine market are focusing on advancing innovative vaccine candidates, such as live-attenuated and next-generation chikungunya vaccines, to address the growing need for effective prevention of viral-induced joint pain and long-term arthritic complications, particularly in vulnerable populations. Live-attenuated and next-generation chikungunya vaccines refer to advanced vaccine formulations designed to prevent chikungunya virus infection by eliciting strong and long-lasting immune responses, where live-attenuated vaccines use weakened forms of the virus to closely mimic natural infection and provide durable protection, and next-generation vaccines employ modern platforms such as viral vectors, recombinant proteins, or novel attenuation technologies to enhance safety, immunogenicity, and broader population applicability. For example, in June 2025, Bavarian Nordic A/S, a Denmark-based biotechnology company, initiated a Phase 3 clinical study of its chikungunya vaccine in children, aiming to expand protection to pediatric populations in endemic regions, where early-life exposure can lead to significant disease burden. The progression to late-stage clinical evaluation reflects growing confidence in the vaccine’s safety and immunogenicity profile and underscores efforts to broaden age indications, strengthen population-level immunity, and reduce the long-term impact of chikungunya-associated viral arthritis globally.

In December 2024, Valneva SE, a France-based biotech firm, entered into a partnership with the Serum Institute of India for its single-shot chikungunya vaccine under an exclusive licensing agreement. Through this collaboration, the partners intend to increase access to the vaccine across Asia and support wider distribution to low- and middle-income countries, leveraging local manufacturing and regulatory capabilities. The Serum Institute of India is an India-based company specializing in producing and distributing affordable vaccines at large scale for public health markets worldwide.

Major companies operating in the viral arthritis vaccine market are Bavarian Nordic A/S, Serum Institute of India Private Limited, Valneva SE, Bharat Biotech International Limited, Panacea Biotec Ltd., The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.

Tariffs are affecting the viral arthritis vaccine market by increasing the cost of imported bioreactor equipment, cold chain systems, and specialized vaccine inputs. Higher duties on pharmaceutical manufacturing tools and raw materials are raising production and distribution costs. Regions dependent on imported vaccine production components are seeing higher capital and operating expenses. Advanced platform vaccines using specialized inputs are more exposed to tariff pressure. Finished vaccine demand remains strong despite cost shifts. At the same time, tariffs are encouraging domestic vaccine manufacturing capacity and local supply chains. This supports regional biotech producers and contract manufacturers.

The viral arthritis vaccine market research report is one of a series of new reports that provides viral arthritis vaccine market statistics, including viral arthritis vaccine industry global market size, regional shares, competitors with a viral arthritis vaccine market share, detailed viral arthritis vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the viral arthritis vaccine industry. This viral arthritis vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A viral arthritis vaccine is a preventive immunization developed to trigger immune protection against viruses that cause arthritis, including Chikungunya virus, Ross River virus, and other arthritogenic viruses. It works to lower infection risk, reduce disease severity, and prevent long-term joint complications by blocking viral entry and replication. It aims to prevent acute illness and chronic inflammatory arthritis while minimizing immune-related joint damage in exposed or high-risk populations.

The primary types of viral arthritis vaccines include viral arthritis vaccine, live, and viral arthritis vaccine, inactivated. Viral arthritis vaccine, live, refers to vaccines that employ a weakened form of the virus to stimulate immunity against viral arthritis. These vaccines target viruses such as chikungunya virus, rubella virus, parvovirus, and other viruses causing viral arthritis. They are applied across farms and individual use, and are administered to end users including hospitals and clinics, vaccination centers, homecare, and government programs.

The viral arthritis vaccine market consists of sales of live-attenuated viral vaccines, inactivated viral vaccines, virus-like particle-based vaccines, recombinant subunit vaccines, messenger ribonucleic acid-based vaccines, and viral vector-based vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.